Výpis publikací

LADUNGOVÁ, Adriana; Filio STYLIANOU; Helena PESCHELOVÁ; Yusuf LODHI; Lenka DOSTÁLOVÁ; Narendra Varma GOTTUMUKKALA a Michal ŠMÍDA. EXPLORING VENETOCLAX RESISTANCE MECHANISMS IN AML CELLS THROUGH GENOME-WIDE CRISPR SCREENS AND DRUG PROFILING. In III. ČESKÝ HEMATOLOGICKÝ A TRANSFUZIOLOGICKÝ SJEZD in Transfuze a Hematologie Dnes. 2024.

PESCHELOVÁ, Helena; Veronika MANČÍKOVÁ; Lenka DOSTÁLOVÁ; Adriana LADUNGOVÁ; Dominika ŠKRNOVÁ; Václav HEJRET a Michal ŠMÍDA. CRISPR/Cas9 technology as a useful tool in the study of chornic lymphocytic leukemia. In CRISPR as a research tool in cancer and regenerative medicine, Stockholm, Švédsko. 2023.

PESCHELOVÁ, Helena; Veronika KOZLOVÁ; Veronika MANČÍKOVÁ; Lenka DOSTÁLOVÁ; Adriana LADUNGOVÁ; Dominika ŠKRNOVÁ; Václav HEJRET a Michal ŠMÍDA. CRISPR/Cas9 technology as a useful tool in the study of chronic lymphocytic leukemia. In PhD and PostDoc RETREAT, Sněžné, Milovy. 2023.

LADUNGOVÁ, Adriana; Helena PESCHELOVÁ; Lenka DOSTÁLOVÁ; Yusuf LODHI; Narendra Varma GOTTUMUKKALA; Jiří MAYER a Michal ŠMÍDA. Exploring the mechanisms of Venetoclax resistence via drug screening and genome-wide CRISPR screening. In The 65th ASH Annual Meeting and Exposition, San Diego, California, USA in Blood. 2023.

DOSTÁLOVÁ, Lenka; Aneta LEDEREROVÁ; Helena PESCHELOVÁ; Tomáš LOJA a Michal ŠMÍDA. Genome-wide CRISPR/Cas9 knockout screening revealed genes involved in CD20 regulation. In CRISPR as a research tool in cancer and regenerative medicine, Stockholm, Švédsko. 2023.

DOSTÁLOVÁ, Lenka; Aneta LEDEREROVÁ; Helena PESCHELOVÁ; Tomáš LOJA a Michal ŠMÍDA. Genome-wide CRISPR/Cas9 knockout screening revealed genes involved in CD20 regulation in rituximab-resistant cells. In PhD and PostDoc RETREAT, Sněžné, Milovy. 2023.

DOSTÁLOVÁ, Lenka; Aneta LEDEREROVÁ; Helena PESCHELOVÁ; Tomáš LOJA a Michal ŠMÍDA. Identification of novel targets that upregulate CD20 expression in rituximab-resistant cells with the use of genomewide CRISPR screening. In XX. International Workshop on CLL (iwCLL 2023), Boston, USA. 2023.

DOSTÁLOVÁ, Lenka; Aneta LEDEREROVÁ; Helena PESCHELOVÁ; Václav HEJRET a Michal ŠMÍDA. CRISPR/Cas9 knockout screening revealed genes involved in CD20 regulation. In Annual PhD conference Biomedical sciences, Brno. 2022.

LODHI, Yusuf; Adriana LADUNGOVÁ; Daniel BUŠA; Helena PESCHELOVÁ; Martin ČULEN a Michal ŠMÍDA. Genome-wide Screening Optimizations and High-throughput Compound Screening to Identify Novel Treatment Options in Venetoclax-resistant AML. In Annual PhD conference Biomedical sciences, Brno. 2022.

DAVE, Zankruti; Olga VONDÁLOVÁ BLANÁŘOVÁ; Štěpán ČADA; Pavlína JANOVSKÁ; Nikodém ZEZULA; Martin BĚHAL; Kateřina HANÁKOVÁ; Sri Ranjani GANJI; Pavel KREJČÍ; Kristína GÖMÖRYOVÁ; Helena PESCHELOVÁ; Michal ŠMÍDA; Zbyněk ZDRÁHAL; Šárka PAVLOVÁ; Jana KOTAŠKOVÁ; Šárka POSPÍŠILOVÁ a Vítězslav BRYJA. Lyn Phosphorylates and Controls ROR1 Surface Dynamics During Chemotaxis of CLL Cells. Frontiers in Cell and Developmental Biology. Frontiers Media SA, 2022, roč. 10, February 2022, s. 1-11. ISSN 2296-634X. Dostupné z: https://dx.doi.org/10.3389/fcell.2022.838871.

LADUNGOVÁ, Adriana; Daniel BUŠA; Helena PESCHELOVÁ; Yusuf LODHI; Martin ČULEN a Michal ŠMÍDA. Prediction of novel treatment options for CLL and AML cells based on drug repurposing. In CEITEC PhD Conference, Brno. 2022.

DOSTÁLOVÁ, Lenka; Aneta LEDEREROVÁ; Veronika KOZLOVÁ; Helena PESCHELOVÁ; Adriana LADUNGOVÁ; Veronika MANČÍKOVÁ a Michal ŠMÍDA. CD19 promoter hypermethylation as means of antigen-negative escape to CART-19 therapy. In XIX International Workshop on Chronic Lymphocytic Leukemia (iwCLL). 2021.

LADUNGOVÁ, Adriana; Helena PESCHELOVÁ; Veronika KOZLOVÁ a Michal ŠMÍDA. Drug repositioning in genetically defined CLL cases reveals a potentional novel therapeutic use for approved drugs. In II. Český hematologický a transfuziologický sjezd v Transfuze a Hematologie Dnes (2021). 2021.

LEDEREROVÁ, Aneta; Lenka DOSTÁLOVÁ; Veronika KOZLOVÁ; Helena PESCHELOVÁ; Adriana LADUNGOVÁ; Martin ČULEN; Tomáš LOJA; Jan VERNER; Šárka POSPÍŠILOVÁ; Michal ŠMÍDA a Veronika MANČÍKOVÁ. Hypermethylation of CD19 promoter enables antigen-negative escape to CART-19 in vivo and in vitro. Journal for ImmunoTherapy of Cancer. Switzerland: Springer International Publishing AG, 2021, roč. 9, č. 8, s. 1-8. ISSN 2051-1426. Dostupné z: https://dx.doi.org/10.1136/jitc-2021-002352.

DOSTÁLOVÁ, Lenka; Aneta LEDEREROVÁ; Veronika KOZLOVÁ; Helena PESCHELOVÁ; Adriana LADUNGOVÁ; Tomáš LOJA; Jan VERNER; Šárka POSPÍŠILOVÁ; Veronika MANČÍKOVÁ a Michal ŠMÍDA. In vivo antigen-negative escape to CART-19 caused by CD19 promotor hypermethylation. In II. Český hematologický a transfuziologický sjezd v Transfuze a Hematologie Dnes (2021). 2021.

KOZLOVÁ, Veronika; Aneta LEDEREROVÁ; Adriana LADUNGOVÁ; Helena PESCHELOVÁ; Pavlína JANOVSKÁ; A. SLUSARCZYK; J. DOMAGALA; Pavel KOPČIL; Viera VAKULOVÁ; Jan OPPELT; Vítězslav BRYJA; Michael DOUBEK; Jiří MAYER; Šárka POSPÍŠILOVÁ a Michal ŠMÍDA. CD20 is dispensable for B-cell receptor signaling but is required for proper actin polymerization, adhesion and migration of malignant B cells. Plos one. San Francisco: Public Library Science, 2020, roč. 15, č. 3, s. 0229170-229189. ISSN 1932-6203. Dostupné z: https://dx.doi.org/10.1371/journal.pone.0229170.

LEDEREROVÁ, Aneta; Veronika KOZLOVÁ; Veronika MANČÍKOVÁ; Helena PESCHELOVÁ; J. PERSSON; B. SCHMIERER; Michael DOUBEK; Jiří MAYER; Šárka POSPÍŠILOVÁ a Michal ŠMÍDA. Combination of epigenetic drug screen and CRISPR knockout screen revealed involvement of aurora kinases and Cullin 3 in CD20 regulation. In 25th Congress of European Hematology Association, Amsterdam, Nizozemsko, in HemaSphere. 2020.

PESCHELOVÁ, Helena; Veronika KOZLOVÁ; Veronika MANČÍKOVÁ; Adriana LADUNGOVÁ; Václav HEJRET a Michal ŠMÍDA. CRISPR/CAS9 technology: a useful tool in the study of chronic lymphocytic leukemia. In XXth Interdisciplinary meeting of young researchs and students in the field of chemistry, biochemistry, molecular biology and biomaterials in Chemické listy. 2020. ISSN 2336-7202.

PESCHELOVÁ, Helena; Lenka DOSTÁLOVÁ; Veronika KOZLOVÁ; Aneta LEDEREROVÁ; Václav HEJRET a Michal ŠMÍDA. Genome-wide CRISPR/Cas9 screening reveals novel target genes, whose inactivation is able to upregulate surface expression of immunotherapy target CD20. In 25th Congress of European Hematology Association, Amsterdam, Nizozemsko, in HemaSphere. 2020.

MANČÍKOVÁ, Veronika; Veronika KOZLOVÁ; Helena PESCHELOVÁ; Jiří MAYER; Šárka POSPÍŠILOVÁ a Michal ŠMÍDA. Impact of genetics on the performance of anti-CD 19 chimeric antigen receptor T cells in chronic lymphocytic leukemia. In 2nd European CAT T Cell Meeting. 2020.

MANČÍKOVÁ, Veronika; Helena PESCHELOVÁ; Veronika KOZLOVÁ; Aneta LEDEREROVÁ; Adriana LADUNGOVÁ; Jan VERNER; Tomáš LOJA; František FOLBER; Jiří MAYER; Šárka POSPÍŠILOVÁ a Michal ŠMÍDA. Performance of anti-CD19 chimeric antigen receptor T cells in genetically defined classes of chronic lymphocytic leukemia. Journal for ImmunoTherapy of Cancer. Switzerland: Springer International Publishing AG, 2020, roč. 8, č. 1, s. 000471-481. ISSN 2051-1426. Dostupné z: https://dx.doi.org/10.1136/jitc-2019-000471.

PESCHELOVÁ, Helena; Veronika KOZLOVÁ; Veronika MANČÍKOVÁ; Adriana LADUNGOVÁ; Václav HEJRET a Michal ŠMÍDA. The use of CRISPR/Cas9 technology in the study of chronic lymphocytic leukemia. In CEITEC PhD Conference. 2020.

PESCHELOVÁ, Helena; Veronika KOZLOVÁ; Václav HEJRET a Michal ŠMÍDA. CRISPR/Cas9 gene editing and functional screening in chronic lymphocytic leukemia. In Joint retreat 2019, Kouty u Ledče nad Sázavou. 2019. ISBN 978-80-210-9300-3.

MANČÍKOVÁ, Veronika; Veronika KOZLOVÁ; Helena PESCHELOVÁ; Jiří MAYER; Šárka POSPÍŠILOVÁ a Michal ŠMÍDA. Performance of α-CD19 Chimeric Antigen Receptor T cells in genetically defined classes of Chronic Lymphocytic Leukemia. In 5th Annual International Conference New Concepts in Lymphoid Malignancies, Estoril, Portugalsko. 2019.

PESCHELOVÁ, Helena; Veronika KOZLOVÁ; Václav HEJRET a Michal ŠMÍDA. The use of CRISPR/Cas9 technology in the study of chronic lymphocytic leukemia. In Biomania, Brno. 2019.

PESCHELOVÁ, Helena; Veronika KOZLOVÁ; Šárka POSPÍŠILOVÁ a Michal ŠMÍDA. CRISPR/Cas9-mediated gene knockout of TP53 and ATM in HG3 cell line: models for chronic lymphocytic leukemia. In CEITEC PHD and POSTDOC RETREAT. 2018.

MIKULÁŠOVÁ, Aneta; Jan SMETANA; Markéta WAYHELOVÁ; Helena JANYŠKOVÁ; Viera SANDECKÁ; Zuzana KUFOVÁ; Martina ALMÁŠI; Jiří JARKOVSKÝ; Evzen GREGORA; Petr KESSLER; Marek WROBEL; Brian WALKER; Christopher WARDELL; Gareth MORGAN; Roman HÁJEK a Petr KUGLÍK. Genomewide profiling of copy-number alteration in monoclonal gammopathy of undetermined significance. European Journal of Haematology. Wiley-Blackwell Munksgaard, 2016, roč. 97, č. 6, s. 568-575. ISSN 0902-4441. Dostupné z: https://dx.doi.org/10.1111/ejh.12774.

MIKULÁŠOVÁ, Aneta; Jan SMETANA; Markéta WAYHELOVÁ; Helena JANYŠKOVÁ; Samuel Adeyinka OKUBOTE; Roman HÁJEK a Petr KUGLÍK. Whole genome amplification effect on segmental copy-number changes and copy-number neutral loss of heterozygosity analysis by oligonucleotide-array based comparative genomic hybridization in human myeloma cell line. International Journal of Clinical and Experimental Pathology. 2016, roč. 9, č. 7, s. 6965-6980. ISSN 1936-2625.